Tamuzimod

Ventyx 的临床研发管线包含多种小分子药物，这些药物有望成为治疗慢性炎症的口服疗法 此次收购将依托礼来公司在炎症介导疾病领域已建立的能力 印第安纳波利斯，2026 年 1 月 7 日 / 美通社 /—— 礼来公司（纽约证券交易所代码：LLY）与 Ventyx 生物科学公司（纳斯达克代码：VTYX）今日宣布，礼来公司已达成收购 Ventyx 的最终协议。Ventyx 生物科学公司是一家总部位于圣地亚哥的临床阶段生物制药公司，专注于为炎症介导疾病患者开发创新口服疗法。 Ventyx 正在开发一系列小分子疗法，包括 NLRP3 抑制剂，旨在治疗多种疾病状态下的炎症，这些疾病存在大量未被满足的医疗需求。其中包括在心脏代谢疾病、神经退行性疾病和炎症性疾病等领域的应用机会。该公司的临床阶段项目以关键免疫通路为靶点，目标是提供比现有治疗方法更优的疗效和安全性。 “越来越多的证据表明，炎症是许多慢性疾病的关键驱动因素，” 礼来研究实验室首席科学与产品官兼总裁 Daniel M. Skovronsky 医学博士、哲学博士表示，“Ventyx 的临床阶段研发管线满足了慢性炎症介导疾病对更好治疗方案的迫切需求，并进一步增强了我们在心脏代谢健康、神经退行性疾病和自身免疫等重点领域为患有疑难疾病的患者带来有意义进展的能力。” “我们的一流 NLRP3 抑制剂产品组合能够调节残余炎症和慢性炎症，如今这些炎症已被认为是多种神经炎症、心脏代谢疾病和心血管疾病的主要风险因素，”Ventyx 生物科学公司首席执行官 Raju Mohan 博士说，“我们相信礼来是理想的战略合作伙伴，它拥有无与伦比的资源、对创新口服药物的热情，以及致力于推进新型疗法的决心，这些疗法将满足患有这些衰弱性疾病和病症患者的大量未被满足的需求。” 根据协议条款，礼来将以全现金交易方式收购 Ventyx 的全部流通股，每股普通股价格为 14.00 美元（合计股权价值约 12 亿美元）。该交易不受任何融资条件限制，预计将于 2026 年上半年完成，前提是获得 Ventyx 股东的批准以及满足其他惯例成交条件，包括监管部门的批准。 交易完成时支付的收购价格较 2026 年 1 月 5 日结束的 Ventyx 普通股 30 天成交量加权平均交易价格溢价约 62%。两家公司的董事会均已批准该交易。 为表明对该交易的承诺，与新科学风险投资公司相关联的实体以及 Ventyx 的所有董事和高管已签署投票支持协议，同意投票批准该交易。这些协议所涉及的股份约占 Ventyx 流通普通股总数的 10%。 礼来将在交易完成后根据公认会计原则（GAAP）确定该交易的会计处理方式。此后，该交易将反映在礼来的财务业绩和财务指引中。 美国银行证券公司担任礼来的独家财务顾问，罗普斯 & 格雷律师事务所担任礼来的法律顾问。杰富瑞有限责任公司担任 Ventyx 的首席财务顾问，美驰公司担任 Ventyx 的联合财务顾问。威尔逊・桑西尼・古奇・罗沙迪律师事务所担任 Ventyx 的法律顾问。 关于礼来礼来是一家将科学转化为治疗手段的制药公司，致力于让全球人民的生活更美好。近 150 年来，我们一直在开创改变生活的新发现，如今我们的药物帮助着全球数千万人。我们的科学家利用生物技术、化学和基因药物的力量，正紧急推进新的发现，以解决世界上一些最重大的健康挑战：重新定义糖尿病护理；治疗肥胖并遏制其最具破坏性的长期影响；推进阿尔茨海默病的防治工作；为一些最令人衰弱的免疫系统疾病提供解决方案；以及将最难治疗的癌症转化为可控制的疾病。在迈向更健康世界的每一步中，我们都被一件事所激励：让更多人的生活更美好。这包括开展反映世界多样性的创新临床试验，并努力确保我们的药物可及且负担得起。F-LLY 关于 Ventyx 生物科学公司Ventyx 生物科学公司是一家临床阶段的生物制药公司，致力于为炎症介导疾病患者开发创新口服疗法。我们在药物化学、结构生物学和免疫学方面的专业知识，使我们能够为具有高度未满足医疗需求的疾病发现差异化的口服小分子疗法，而我们在临床开发方面的丰富经验则使这些候选药物能够快速推进临床试验。我们的 NLRP3 抑制剂产品组合包括 VTX2735（一种外周限制性 NLRP3 抑制剂，处于治疗复发性心包炎的 2 期开发阶段）和 VTX3232（一种可穿透中枢神经系统的 NLRP3 抑制剂，在最近报告的 2 期试验中显示出心血管风险因素的显著降低）。此外，VTX3232 最近完成了一项针对早期帕金森病的 2 期生物标志物研究。我们更广泛的炎症性肠病产品组合包括两种 2 期化合物：他莫昔莫德（VTX002，一种 S1P1R 调节剂）和 VTX958（一种 TYK2 抑制剂）。 Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation Acquisition builds on Lilly's established capabilities in inflammatory-mediated diseases INDIANAPOLIS, Jan. 7, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Ventyx Biosciences, Inc. (Nasdaq: VTYX), a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases, today announced entry into a definitive agreement for Lilly to acquire Ventyx. Ventyx is developing a pipeline of small molecule therapeutics, including NLRP3 inhibitors, designed to treat inflammation across a broad range of disease states with high unmet need. These include opportunities across cardiometabolic disorders, neurodegenerative diseases and inflammatory disorders. The company's clinical-stage programs target key immune pathways with the goal of offering improved efficacy and safety compared to existing treatments. "There is increasing evidence that inflammation is a key driver of many chronic diseases," said  Daniel M. Skovronsky, M.D., Ph.D., chief scientific and product officer, and president of Lilly Research Laboratories. "Ventyx's clinical-stage pipeline addresses a critical need for better treatment options across diseases mediated by chronic inflammation and further strengthens our ability to deliver meaningful advances for patients living with challenging diseases across focus areas of cardiometabolic health, neurodegeneration and autoimmunity." "Our portfolio of class-leading NLRP3 inhibitors modulate residual and chronic inflammation that is now recognized as a major risk factor in a host of neuroinflammatory, cardiometabolic and cardiovascular diseases," said  Raju Mohan, Ph.D., chief executive officer of Ventyx Biosciences. "We believe that Lilly is an ideal strategic partner, with unparalleled resources, a passion for innovative oral drugs and a commitment to advance novel therapies that fill a vast unmet need for patients suffering from these debilitating diseases and disorders." Under the terms of the agreement, Lilly will acquire all of the outstanding shares of Ventyx for $14.00 per share of common stock in an all-cash transaction (equal to an aggregate equity value of approximately $1.2 billion). The transaction is not subject to any financing condition and is expected to close in the first half of 2026, subject to approval by Ventyx stockholders and satisfaction of other customary closing conditions, including regulatory approvals. The purchase price payable at closing represents a premium of approximately 62% to the 30-day volume-weighted average trading price of Ventyx's common stock ended on January 5, 2026. The boards of directors of both companies have approved the transaction. To demonstrate their commitment to the transaction, entities affiliated with New Science Ventures and all directors and officers of Ventyx have signed voting and support agreements whereby they agree to vote to approve the transaction. The shares subject to the agreements represent a total of approximately 10% of Ventyx's outstanding common stock. Lilly will determine the accounting treatment of this transaction in accordance with Generally Accepted Accounting Principles (GAAP) upon closing. This transaction will thereafter be reflected in Lilly's financial results and financial guidance. BofA Securities, Inc. is acting as exclusive financial advisor and Ropes & Gray is acting as legal counsel to Lilly. Jefferies LLC is acting as lead financial advisor and with Moelis & Company LLC acting as co-financial advisor to Ventyx. Wilson, Sonsini Goodrich & Rosati is acting as legal counsel to Ventyx. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. F-LLY About Ventyx BiosciencesVentyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with inflammation-mediated diseases. Our expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated oral small molecule therapeutics for conditions with high unmet medical need, and our extensive experience in clinical development allows the rapid progression of these drug candidates through clinical trials. Our portfolio of NLRP3 inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor that demonstrated significant reductions in cardiovascular risk factors in a recently reported Phase 2 trial.  In addition, VTX3232 recently completed a Phase 2 biomarker study in early-stage Parkinson's disease.  Our broader inflammatory bowel disease portfolio includes two Phase 2 compounds: tamuzimod (VTX002), a S1P1R modulator and VTX958, a TYK2 inhibitor.

San Diego-based Ventyx Biosciences has made no secret of the fact that it was hoping to find additional pharma backing. \n Ventyx Biosciences has achieved its goal of securing Big Pharma commitment to its pipeline, with Eli Lilly swooping in to buy the inflammation biotech outright for $1.2 billion.The San Diego-based company has made no secret of the fact that it was hoping to find additional pharma backing. Sanofi had already secured the right to first negotiation for Ventyx’s Parkinson’s and cardiovascular disease candidate VTX3232 as part of a $27 million investment the French pharma made in the biotech in 2024.A first readout from a phase 2 study of VTX3232 last June tied the NLRP3 inhibitor to drops in biomarkers of NLRP3 inhibition as well as improvements in Parkinson’s motor and non-motor symptoms.At the time, Ventyx CEO Raju Mohan, Ph.D., acknowledged that Sanofi’s right of first negotiation wouldn’t formally start until the second VTX3232 readout. But the CEO gave a strong hint that the company didn’t want to wait that long to secure a Big Pharma partner.“Sanofi is not restricted to waiting until the second readout,\" Mohan said at a Jefferies event in June 2025. “They or anybody else can act any time. We can\'t solicit other folks as part of [the right of first negotiation], but somebody can say, ‘Hey, look, we love your data.’”It sounds like Lilly did just that. The U.S. pharma announced Wednesday that it was paying $14 per share of Ventyx—more than double the $7.50 the stock closed out at Monday. The price tag values Ventyx at around $1.2 billion, Lilly explained in a Jan. 7 release. VTX3232 doesn’t only have potential for Parkinson’s patients. In October, Ventyx read out data from a separate phase 2 study demonstrating that the drug cut levels of a biomarker for stroke and other serious risks by almost 80% within a week. That trial looked at VTX3232 as a monotherapy as well as an add-on to Novo Nordisk’s blockbuster weight loss drug semaglutide.Beyond VTX3232, Ventyx has another NLRP3 inhibitor, dubbed VTX2735, in phase 2 studies for a type of heart inflammation called recurrent pericarditis. There are also two inflammatory bowel disease drugs in phase 2 development—an S1P1R modulator called tamuzimod and a TYK2 inhibitor called VTX958.Mohan described Lilly as an “ideal strategic partner,” pointing to the pharma’s “unparalleled resources, a passion for innovative oral drugs and a commitment to advance novel therapies.”“Our portfolio of class-leading NLRP3 inhibitors modulate residual and chronic inflammation that is now recognized as a major risk factor in a host of neuroinflammatory, cardiometabolic and cardiovascular diseases,” Mohan added.Explaining the rationale behind the deal, Lilly Chief Scientific and Product Officer Daniel Skovronsky, M.D., Ph.D., alluded to “increasing evidence that inflammation is a key driver of many chronic diseases.” “Ventyx\'s clinical-stage pipeline addresses a critical need for better treatment options across diseases mediated by chronic inflammation and further strengthens our ability to deliver meaningful advances for patients living with challenging diseases across focus areas of cardiometabolic health, neurodegeneration and autoimmunity,” Skovronsky added.William Blair analysts said yesterday’s deal “demonstrates clear interest from Big Pharma in the NLRP3 inhibitor class to address a broad range of neuroinflammatory, cardiometabolic, and cardiovascular diseases.”In a Jan. 8 note, the analysts pointed out that other biopharmas are working in the NLRP3 space, name-checking the likes of Novartis, Neumora, Neurocrine Biosciences, BioAge, NodThera and Monte Rosa Therapeutics.“NLRP3 in the [central nervous system] also represents an intriguing target for obesity and several preclinical studies across NLRP3 inhibitors suggest obesity efficacy in diet-induced-obesity models,” the analysts added. “However, not all NLRP3 inhibitors are CNS-penetrant.”